Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD147-CART in Advanced Hepatocellular Carcinoma
NCT03993743Phase 1Unknown
- Sponsor
- Xijing Hospital
- Start
- May 2019
- Primary completion
- Oct 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD147 CAR T-cells in hepatocellular carcinoma (HCC), sponsored by Xijing Hospital. Primary endpoint: Adverse Events at 12 weeks. Status: unknown.
02
Drugs
CD147 CAR T-cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03993743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993743.